Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound ~~having~~ of the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



(I)

wherein

R^1 is hydrogen,

R^2 is hydrogen or C_{1-20}-alkyl,

R^3 is hydrogen, C_{1-20}-alkyl, C_{4-8}-cycloalkyl, C_{5-8}-cycloalkylenyl, aryl, C_{1-20}-alkoxy, or a group of formula -W-R^8.

R^{3a} is hydrogen or C_{1-20}-alkyl,

R^4 is hydrogen,

R^5 is hydrogen; nitro; halogen; azido; cyano; -S-C_{1-4}-alkyl; -SO-C_{1-4}-alkyl; -SO_2-C_{1-4}-alkyl; -$SONH_2$; C_{1-20}-alkyl unsubstituted or substituted by halogen; or C_{1-20}-alkoxy unsubstituted or substituted by halogen,

R^6 is hydrogen, C_{1-20}-alkyl or halogen,

R^7 is hydrogen, C_{1-20}-alkyl or halogen,

W is C_{1-12}-alkylene, -NH- or -NHC(=O)-,

R^8 is aryl

and at least one of R^5, R^6 and R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2, 6-diisopropylphenyl, and R^{3a} is H.

2. (currently amended) A compound ~~having~~ of the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



(I)

wherein

R^1 is hydrogen,

R^2 is hydrogen or C_{1-4}-alkyl,

R^3 is hydrogen; C_{1-6}-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl and alkylamino; C_{5-7}-cycloalkyl; (hydroxymethyl) cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C_{1-4}-alkyl, hydroxy, methoxy, nitro, methylsulfonyl, and trifluoromethylthio; or a group offormula-W-R^8,

R^{3a} is hydrogen, C_{1-4}-alkyl,

R^4 is hydrogen,

R^5 is hydrogen; nitro; halogen; C_{1-4}-alkyl, unsubstituted or substituted by halogen; or C_{1-4}-alkoxy unsubstituted or substituted by halogen,

R^6 is hydrogen, C_{1-6}-alkyl or halogen,

R^7 is hydrogen, methyl or halogen,

W is C_{1-4}-alkylene unsubstituted or substituted by halogen, hydroxy, C_{1-4}-alkyl or alkoxy; -NH-; or -NHC (=O)-,

R^8 is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C_{1-4}-allyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluoromethylthio;

and at least one of R^5, R^6 and R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2,6-diisopropylphenyl, and R^{3a} is H.

3. (currently amended) A compound ~~having~~ of the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



(I)

wherein

R^1 is hydrogen,

R^2 is hydrogen, methyl or ethyl,

R^3 is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, 1-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dimethylamino)propyl, 6-(hydroxymethyl)cyclohex-3-en-1-yl, 3-hydroxyphenyl, 3-fluorophenyl,3-(2-pyridin-2-ylethyl) phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3-methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl,2-chloro-6-fluorobenzyl, 2-[(trifluoromethyl) thio] benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, [4-bromophenyl)amino, or methoxy,

R^{3a} is hydrogen, methyl,

R^4 is hydrogen,

R^5 is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl, isopropyl, nitro or halogen,

R^6 is hydrogen, methyl or Cl,

R^7 is hydrogen, methyl, Br, F or C1,

and at least one of R^5, R^6 or R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2,6-diisopropylphenyl and R^{3a} is H.

4. (previously presented) A compound according to claim 1 wherein R^2 is hydrogen or methyl.

5. (previously presented) A compound according to claim 1 wherein R^3 is hydrogen.

6. (previously presented) A compound according to claim 1 wherein R^{3a} is hydrogen.

7. (previously presented) A compound according to claim 1 wherein R^5 is halogen or

trifluoromethyl.

8. (previously presented) A compound according to claim 1 wherein R^6 is hydrogen.

9. (previously presented) A compound according to claim 1 wherein R^7 is hydrogen, Br, or F.

10. (previously presented) A compound according to claim 1 wherein R^2 is C_{1-20}-alkyl and the carbon atom to which R^2 is attached is in the "S"-configuration.

11. (previously presented) A compound selected from

2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5,7-dibromo-2-oxo-2,3-dihydro-1H-indol-1-y1)acetamide;

2-(5-nitro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;

(2R)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;

(2S)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;

2-[2-oxo-5-(fluoromethoxy)-2,3-dihydro-1H-indo1-1-yl)acetamide;

2-(5-isopropyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-ethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-1-y1)acetamide;

2-(5,7-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(2-oxo-5-propyl-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(2-oxo-5-(trifluoromethyl)-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5,6-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(7-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(6-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide;

(+)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-l-yl)butanamide;

(-)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide;

2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;

(+)-2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;

(-)-2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;

2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;

(-)-2-(5-bromo-2-oxo-2,3-dihydr0-1H-indol-1-y1)propanamide;

(+)-2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;

2-(5-chloro-7-fluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxyphenyl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-fluoroplenyl)acetamide;

2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(4-hydroxy-3-methoxybenzy1)acetamide;

2-(5-chloro2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[4-(methylsulfonyl)benzyl]acetamide;

N'- (4-bromophenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetohydrazide;

N-butyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxypropyl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[3-(dimethylamino)propyl]acetamide;

ethyl{[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]amino}acetate;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-ethoxypropyl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-fluoroethyl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methoxy-N-methylacetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dimethylphenyl)acetamide;

N-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxy-2,2-dimethylpropyl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[1-(hydroxymethyl)propyl]acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-hydroxy-2-phenylethyl) acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(2-chlorophenylethyl]acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(4-methylphenyl)ethyl]acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4,5,6-tetrahydro-1-benzazocin-1(2H)-yl)propyl]acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-nitrobenzyl)acetamide;

N-(2-chloro-6-fluorobenzyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide;

N-benzyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methylacetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-{2-[(trifluoromethyl) thio] benzyl}acetamide; ~~and~~

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-cycloheptylacetamide; and pharmaceutically acceptable salts thereof.

12.-14. (canceled)

15. (currently amended) A compound ~~having~~ of the formula VI or a pharmaceutically acceptable salt thereof or a stereoisomeric forms thereof,



(VI)

wherein

R^1 is hydrogen,

R^2 is hydrogen or C_{1-20}-alkyl,

R^3 is hydrogen, C_{1-20}-alkyl, C_{4-8}-cycloalkyl, C_{5-8}-cycloalkylenyl, or aryl, C_{1-20}-alkoxy, or a group of formula -W-R^8,

R^{3a} is hydrogen or C_{1-20}-alkyl,

R^4 is hydrogen,

R^5 is hydrogen; halogen; azido; cyano; -S-C_{1-4}-alkyl; -SO-C_{1-4}-alkyl; -SO_2-C_{1-4}-alkyl; -$SONH_2$; or C_{1-20}-alkyl unsubstituted or substituted by halogen,

R^6 is hydrogen, C_{1-20}-alkyl or halogen,

R^7 is hydrogen, C_{2-20}-alkyl or halogen,

W is C_{1-12}-alkylene, -NH- or -NHC(=O)-,

R^8 is aryl and

at least one of R^5, R^6 and R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2, 6-diisopropylphenyl, and R^{3a} is H.

16. (canceled)

17. (previously presented) A compound which is selected from the group consisting of:

2-(5-chloro-1H-indol-1-yl)propanamide;

2-(7-chloro-1H-indol-1-yl)acetamide;

2-(6-chloro-1H-indol-1-yl)acetamide;

2-(5-chloro-1H-indol-1-yl)butanamide;

2-(5-methyl-1H-indol-1-yl)propanamide;

2-(5-bromo-1H-indol-1-yl)propanamide;

2-(7-fluoro-1H-indol-1-yl)acetamide;

2-(5-bromo-1H-indol-1-yl)acetamide;

2-(5-fluoro-1H-indol-1-yl)acetamide;

2-(5-chloro-1H-indol-1-yl)acetamide;

(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetic acid; and

pharmaceutically acceptable salts thereof.

18. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier.

19.-21. (canceled)